Obesity and Obstructive Sleep Apnea (OSA) in Children

Sponsor
Assaf-Harofeh Medical Center (Other)
Overall Status
Unknown status
CT.gov ID
NCT01135147
Collaborator
(none)
100
1
2

Study Details

Study Description

Brief Summary

The goal of this research is to study the prevalence of sleep disordered breathing and associated morbidity in obese children and to examine the role of diet and physical activity in the treatment of sleep-disordered breathing in obese children.

Condition or Disease Intervention/Treatment Phase
  • Behavioral: Diet
  • Procedure: Surgery
N/A

Detailed Description

In a prospective cohort study, obese children will be recruited. After informed consent is obtained, all children will complete a standardized sleep questionnaire and a pediatric daily sleepiness scale questionnaire. All participants will undergo a complete physical examination, blood tests for lipid profile, liver enzymes, and Glucose and insulin will be obtained, and liver sonography will be performed to assess for the presence of fatty liver. Nasopharyngeal radiographs will be used to assess adenoidal size based on the method by Cohen and Konak. A standard in-laboratory, overnight polysomnography will be performed, within 2 weeks of enrollment to the study, in the sleep laboratory at Asaf Harofeh Medical Center. Children with severe obstructive sleep apnea, defined as apnea hypopnea index (AHI) > 15 will undergo adenotonsillectomy. All children will be referred for a dietary and physical education program. The first visit with the dietician will be considered day 1 of the study. Children will than be followed monthly by a dietician. After three months of follow-up, subjects will be divided into two groups. Group 1 will include all children who had AHI > 2 on the initial polysomnography (including children who underwent adenotonsillectomy for AHI > 15), and group 2 will consist of children who had AHI < 2 on the initial PSG. Children of group 2 will continue monthly dietary visits as before. Children from group 1 will undergo a second evaluation including questionnaires, laboratory blood tests, liver sonography, nasopharyngeal radiographs, and polysomnography. Children who demonstrate reduction in the AHI based on PSG will be offered to continue with dietary treatment alone. Children with no change in the AHI based on PSG will be offered to undergo adenotonsillectomy in addition to continued dietary management. All children will be followed for a total duration of six months. After six months, all children will be re-evaluated by questionnaires, blood tests, liver sonography, and nasopharyngeal radiographs. Polysomnography will be performed in all children who had an AHI > 2 on the second PSG.

Study Design

Study Type:
Interventional
Anticipated Enrollment :
100 participants
Allocation:
Non-Randomized
Intervention Model:
Single Group Assignment
Masking:
None (Open Label)
Primary Purpose:
Treatment
Official Title:
Dietary Therapy for Obesity-related Sleep-disordered Breathing in Children
Study Start Date :
Jun 1, 2010
Anticipated Primary Completion Date :
Jun 1, 2012

Arms and Interventions

Arm Intervention/Treatment
Experimental: Diet

Patients treated with diet and physical therapy for the entire 6 months of the study

Behavioral: Diet
Dietary therapy and physical education

Active Comparator: Surgery

Patients undergoing adenotonsillectomy at some point of the study period

Procedure: Surgery
Adenotonsillectomy along with diet and physical therapy

Outcome Measures

Primary Outcome Measures

  1. Reduction in apnea hypopnea index (AHI) [3, 6 months]

    Repeat polysomnography to assess change in AHI following treatment

Secondary Outcome Measures

  1. Change in subjective complaints and sleepiness [6 months]

  2. Change in lipid profile and liver enzymes [6 months]

Eligibility Criteria

Criteria

Ages Eligible for Study:
6 Years to 12 Years
Sexes Eligible for Study:
All
Accepts Healthy Volunteers:
Yes
Inclusion Criteria:
  • BMI at or above the 90th percentile
Exclusion Criteria:
  • children with chronic lung or liver disease, mental retardation, syndromes (i.e. prader willi syndrome), endocrine abnormalities (hypothyroidism cushing), chronic medical treatment with oral steroids, or with anti-psychiatric or anti-convulsive medications

Contacts and Locations

Locations

Site City State Country Postal Code
1 Asaf Harofeh Medical Center Zerifin Israel 70300

Sponsors and Collaborators

  • Assaf-Harofeh Medical Center

Investigators

None specified.

Study Documents (Full-Text)

None provided.

More Information

Publications

None provided.
Responsible Party:
, ,
ClinicalTrials.gov Identifier:
NCT01135147
Other Study ID Numbers:
  • 40/09
First Posted:
Jun 2, 2010
Last Update Posted:
Jun 2, 2010
Last Verified:
May 1, 2010
Additional relevant MeSH terms:

Study Results

No Results Posted as of Jun 2, 2010